A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]
<p>Abstract</p> <p>Background</p> <p>Decision aids are often advocated as a means to assist patient and health care provider decision making when faced with complicated treatment or screening decisions. Despite an exponential growth in the availability of decision aids...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2004-05-01
|
| Series: | BMC Cardiovascular Disorders |
| Online Access: | http://www.biomedcentral.com/1471-2261/4/5 |
| _version_ | 1818786991969402880 |
|---|---|
| author | Anderson David Gibson Paul Ghali William A Straus Sharon E Man-Son-Hing Malcolm McAlister Finlay A Cox Jafna Fradette Miriam |
| author_facet | Anderson David Gibson Paul Ghali William A Straus Sharon E Man-Son-Hing Malcolm McAlister Finlay A Cox Jafna Fradette Miriam |
| author_sort | Anderson David |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Decision aids are often advocated as a means to assist patient and health care provider decision making when faced with complicated treatment or screening decisions. Despite an exponential growth in the availability of decision aids in recent years, their impact on long-term treatment decisions and patient adherence is uncertain due to a paucity of rigorous studies. The choice of antithrombotic therapy for nonvalvular atrial fibrillation (NVAF) is one condition for which a trade-off exists between the potential risks and benefits of competing therapies, and the need to involve patients in decision making has been clearly identified. This study will evaluate whether an evidence-based patient decision aid for patients with NVAF can improve the appropriateness of antithrombotic therapy use by patients and their family physicians.</p> <p>Design</p> <p>A multi-center, two-armed cluster randomized trial based in community family practices in which patients with NVAF will be randomized to decision aid or usual care. Patients will receive one of four decision aids depending on their baseline stroke risk. The primary outcome is the provision of "appropriate antithrombotic therapy" at 3 months to study participants (appropriateness defined as per the 2001 American College of Chest Physicians recommendations for NVAF). In addition, the impact of this decision aid on patient knowledge, decisional conflict, well-being, and adherence will be assessed after 3 months, 6 months, and 12 months.</p> |
| first_indexed | 2024-12-18T14:00:41Z |
| format | Article |
| id | doaj.art-6972031440c042b8a99b4b63f967821d |
| institution | Directory Open Access Journal |
| issn | 1471-2261 |
| language | English |
| last_indexed | 2024-12-18T14:00:41Z |
| publishDate | 2004-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj.art-6972031440c042b8a99b4b63f967821d2022-12-21T21:05:20ZengBMCBMC Cardiovascular Disorders1471-22612004-05-0141510.1186/1471-2261-4-5A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]Anderson DavidGibson PaulGhali William AStraus Sharon EMan-Son-Hing MalcolmMcAlister Finlay ACox JafnaFradette Miriam<p>Abstract</p> <p>Background</p> <p>Decision aids are often advocated as a means to assist patient and health care provider decision making when faced with complicated treatment or screening decisions. Despite an exponential growth in the availability of decision aids in recent years, their impact on long-term treatment decisions and patient adherence is uncertain due to a paucity of rigorous studies. The choice of antithrombotic therapy for nonvalvular atrial fibrillation (NVAF) is one condition for which a trade-off exists between the potential risks and benefits of competing therapies, and the need to involve patients in decision making has been clearly identified. This study will evaluate whether an evidence-based patient decision aid for patients with NVAF can improve the appropriateness of antithrombotic therapy use by patients and their family physicians.</p> <p>Design</p> <p>A multi-center, two-armed cluster randomized trial based in community family practices in which patients with NVAF will be randomized to decision aid or usual care. Patients will receive one of four decision aids depending on their baseline stroke risk. The primary outcome is the provision of "appropriate antithrombotic therapy" at 3 months to study participants (appropriateness defined as per the 2001 American College of Chest Physicians recommendations for NVAF). In addition, the impact of this decision aid on patient knowledge, decisional conflict, well-being, and adherence will be assessed after 3 months, 6 months, and 12 months.</p>http://www.biomedcentral.com/1471-2261/4/5 |
| spellingShingle | Anderson David Gibson Paul Ghali William A Straus Sharon E Man-Son-Hing Malcolm McAlister Finlay A Cox Jafna Fradette Miriam A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643] BMC Cardiovascular Disorders |
| title | A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643] |
| title_full | A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643] |
| title_fullStr | A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643] |
| title_full_unstemmed | A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643] |
| title_short | A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643] |
| title_sort | randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation the daafi trial protocol isrctn14429643 |
| url | http://www.biomedcentral.com/1471-2261/4/5 |
| work_keys_str_mv | AT andersondavid arandomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT gibsonpaul arandomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT ghaliwilliama arandomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT straussharone arandomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT mansonhingmalcolm arandomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT mcalisterfinlaya arandomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT coxjafna arandomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT fradettemiriam arandomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT andersondavid randomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT gibsonpaul randomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT ghaliwilliama randomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT straussharone randomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT mansonhingmalcolm randomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT mcalisterfinlaya randomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT coxjafna randomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 AT fradettemiriam randomizedtrialtoassesstheimpactofanantithromboticdecisionaidinpatientswithnonvalvularatrialfibrillationthedaafitrialprotocolisrctn14429643 |